Nootropic racetams, especially Phenylpiracetam, has many years of usage. But yet they are not entirely studied. Most information about Phenylpiracetam clinical studies available only in Russian, while not much info about it in English sources (usually only blogger’s reviews). The reason for this is that Phenylpiracetam is not used in the western medical practice, while being widely used in the CIS countries.

In this article, I will share some information about clinical trials of Phenotropil that I found in Russian Scientific Electronic Library, and briefly describe their methods and conclusions for you.



This clinical trial had three study groups of 21-40 years, old adults. The first group included 68 patients (36 with asthenia and 32 with chronic fatigue syndrome). The second group – 65 patients (45 asthenic patients and 20 with CFS). Third was a control group of 47 patients, 29 suffered from the asthenic syndrome and 18 with chronic fatigue. None of the patients had any somatic disease that could affect their condition.

The first group took 50mg of Phenylpiracetam twice daily (the second dose not later than 3 PM). The total daily dosage increased to 200-250mg (depending on the body weight) during the first week of treatment. The patients of the second group taken 400mg of Piracetam three times a day. The third group has taken imitation of Phenotropil pills as a placebo at the same dosage and schedule as the first group. The length of treatment was four weeks.

The majority of the first group patients felt the therapeutic effect of Phenotropil as soon as daily dosage reached 100mg. They reported such results as “feeling of vigor,” “elimination of brain fog,” accelerated thought and lack of drowsiness. For some patients, sleep time per night was decreased for 1.5 hours without negative impact on their well-being. After the full course of Phenotropil treatment, all patients noted the reduction of asthenia and fatigue symptoms, which can be explained by the stimulatory action of the drug.

The results of attention and memory tests improved significantly compared to groups 2 and 3. The efficiency of Phenylpiracetam treatment was 83.3% for asthenia and 87.5% for chronic fatigue syndrome (myalgic encephalomyelitis). Piracetam efficiency was 48.8% for asthenia and 55% for myalgic encephalomyelitis. Phenotropil showed high efficiency at the treatment of asthenic disorders caused by both organic brain syndrome or neurotic disorders. A better result was shown in the treatment of organic asthenia that confirms the fact, that despite its psychostimulatory action, Phenylpiracetam is nootropic drug.


On the third week of treatment two patients of the first group rejected to take medications because of the increased sexual activity. Total 80% of patients noticed an increase in sexual activity without seeing this effect as negative.

The negative side effect of Phenotropil at the daily dosages of 150-300mg experienced by some users was overstimulation: irritability, anxiety and sleep disturbance. They appeared in the first 14 days of treatment and disappeared after that, without lowering the dosage or any additional medications.

Authors of this study: Akhapkina V., Fedin A., Avedisova A.



The goal of this trial was a study of Phenylpiracetam effects on cognitive functions and cerebral blood flow in adolescents with asthenic conditions.

A total of 39 minors from 14 to 17 years old (22 girls and 17 boys) with complaints of fatigue, irritability, depressed mood, emotional lability, decreased attention, memory problems and headaches participated in the study. They were divided into two groups.

The first group of kids was treated with galvanotherapy (daily for ten days), 400mg of Piracetam twice daily and multivitamins twice daily for 30 days. The second group received only 50mg of Phenotropil in the morning for 30 days.

After treatment, their cerebral blood flow was assessed with Rheoencephalography. The kids also completed the tests of memory, attention, and cognitive functions. As shown in the table, the cerebral blood flow for the first group does not change significantly, while the second group shows significant improvement of the brain blood flow.



Subjective well-being improved in both groups. Both groups performed cognitive tests better after treatment, especially the second group. Bracketed values is percent of patients

The overall result of the treatment in the first group was estimated as good for the nine patients, satisfactory for the seven patients and non-satisfactory for the three patients. For the second group, the result was good for the 15 patients and satisfying for the five patients.

The author of the original article: Zvonareva E.



The goal of this study was to compare effects of “Special pharmacological agent NIKA-3” and different Phenotropil stacks on psychomotor coordination and working performance during precompetitive stress. A total of 9 healthy Special Forces soldiers participated in this research.

Compounds tested in this trial: Phenotropil+Melatonin stack, Phenotropil+Tryptophan stack and Special pharmacological agent “NIKA-3”. The authors did not disclose what’s in the NIKA-3 blend. They only noted that this is “Made of dipeptide with nootropic activity, nootropic of nature origin and actoprotector at specially selected doses.” It is also not available for purchase anywhere, the only information that I was able to get about this compound after hours of research, is a supposed manufacturer.

Phenotropil dosage was 200mg twice daily in the morning and noon, combined with 4.5g of tryptophan or 15mg of melatonin (depending on the group) one hour before bed. The NIKA-3 dosage was one capsule two times a day before training.

After ten days, their psychomotor coordination was tested with the stabilometric platform. Phenotropil+Melatonin stack did not demonstrate any significant results. However, Phenotropil+Tryptophan stack and NIKA-3 showed significant improvement of stabilometry results.

Authors of this study: Korolenok A., Zolotukhina S.



The goal of this clinical trial was to evaluate the Phenylpiracetam effects on cognitive functions of patients suffering from organic brain syndrome. It’s that kind of mental disorders, caused by physiological reason rather than psychological. For example traumatic injury, prenatal brain damage or infectious brain diseases.

Total 36 adolescents with organic brain disorder from 15 to 18 years old participated in this study. Their diagnosis was confirmed by physical and neurological examination, fundoscopy and electroencephalogram (EEG). Patients were divided into two groups: the main group of 21 people and control group of 15 people.

The main complaints of the patients before treatment were headaches, memory and concentration loss, drowsiness, irritability, dizziness, intolerance to noise and poor sleep. Six patients had seizures. Treatment for the first group was 50mg of Phenotropil daily before lunch. The second group received standard treatment with nootropic drugs and B-group vitamins.

Phenotropil demonstrated a significant effect on cognitive functions. Almost all patients noticed memory improvement and relief of their symptoms such as headaches, emotional instability, and asthenia. After beginning the treatment, the positive effects noticed in 3 days by four patients, in 7 days by eight patients, and in 14 days by the rest patients.

Authors of the study: Momynova T., Smagulov B., Miarkovskaya O., Isakov M.

Summing up the results of those clinical trials, we can say, that Phenylpiracetam especially useful for improvement of cognitive functions and well-being of asthenic people. There are not many studies done on the healthy people, but as the study on the healthy soldiers shows, it can improve psychomotor coordination if combined with Tryptophan.